Clinical trials: TACE
Hepatocellular Carcinoma, RFA
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, RFA, TACE
- Trial name
- NCT01415063
- Testing
- RFA, TACE-RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms Malignant
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
- Trial name
- TACE-Ax-HCQ (NCT04873895)
- Testing
- Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Hepatocellular Carcinoma, Bilirubinemia
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
- Trial name
- NCT03259581
- Testing
- Transarterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota
PHENYTOIN/SORAFENIB [VA Drug Interaction], Carcinoma, Hepatocellular
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
TACE is widely used in patients with unresectable HCC. However, it is a non-curative approach; thus ,strategies to further improve the survival of these patients are needed.
- Trial name
- NCT01605734
- Testing
- TACE, sorafenib combined with TACE
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Shandong Cancer Hospital and Institute
Unresectable Hepatocellular Carcinoma
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06896396
- Testing
- Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhiyong Huang
Donafenib
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
This study is expected to recruit 30 patients with unresectable HCC who will be treated with Donafenib combined with PD-1 + TACE.
- Trial name
- NCT05262959
- Testing
- Donafenib, PD-1, TACE
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT02525380
- Testing
- Device(DC Bead)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in…
- Trial name
- NCT04015245
- Testing
- Stronger Neo-Minophagen C
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chimei Medical Center
Inoperable Hepatocellular Carcinoma
MANDARIN (S6371)
To evaluate the efficacy and safety of TheraSphereTM yttrium [90Y] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.
- Trial name
- NCT05016245
- Testing
- TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Boston Scientific Corporation
Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Hepatocellular carcinoma (HCC) is the fourth most common cancer in China, with a crude incidence rate of 26.67 per 100,000 population. Moreover, 357,800 new liver cancer cases are predicted to be diagnosed in China in 2020.
- Trial name
- NCT04127396
- Testing
- Lenvatinib Pill, Transarterial chemoembolization(TACE), Sorafenib
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Ditan Hospital
Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
- Trial name
- NCT04635527
- Testing
- IBI318, cTACE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hepatocellular Carcinoma
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with programmed cell death protein-1 (PD-1) antibody compared with TACE Alone in patients with unresectable…
- Trial name
- NCT03782831
- Testing
- TACE, PD-1 antibody
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
- Trial name
- NCT02854839
- Testing
- MG4101
- Where
- 6 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Unresectable Hepatocellular Carcinoma (HCC)
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07408804
- Testing
- TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- Bangladesh Medical University
Carcinoma, Hepatocellular
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular…
- Trial name
- NCT00082082
- Testing
- Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE)
- Where
- 5 sites in United States
- Sponsor
- SciClone Pharmaceuticals
Colorectal Adenocarcinoma Metastatic to the Liver
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in…
- Trial name
- NCT03783559
- Testing
- TACE, chemotherapy±target therapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Advanced Adult Hepatocellular Carcinoma
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Treatment options for advanced hepatocellular carcinoma (HCC) are limited due to patients' poor condition, advanced tumor, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy.
- Trial name
- NCT02418988
- Testing
- TACE plus rAd-p53 artery injection, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Colorectal Cancer, Liver Metastases
Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis
- Trial name
- NCT04912258
- Testing
- Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University